Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ecallantide - Takeda

Next Previous
Drug Profile

Ecallantide - Takeda

Alternative Names: CB-500,929; DX-88; EPI-KAL2; FOV 2302; Kalbitor

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dyax
  • Developer Cubist Pharmaceuticals; Dyax; Fovea Pharmaceuticals; Neopharm Ltd; Takeda
  • Class Analgesics; Anti-inflammatories; Eye disorder therapies; Peptides; Recombinant proteins; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Plasma kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Suspended Retinal oedema
  • Discontinued Angioedema; Surgical blood loss

Most Recent Events

  • 26 Dec 2022 Ecallantide is still in registration for Hereditary angioedema in Japan (Takeda website, December 2022)
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 21 Dec 2018 Windtree Therapeutics merged with CVie Therapeutics to form Windtree Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top